Lydia Lacerda

2.1k total citations · 1 hit paper
24 papers, 1.7k citations indexed

About

Lydia Lacerda is a scholar working on Pathology and Forensic Medicine, Developmental Neuroscience and Molecular Biology. According to data from OpenAlex, Lydia Lacerda has authored 24 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 7 papers in Developmental Neuroscience and 6 papers in Molecular Biology. Recurrent topics in Lydia Lacerda's work include Cardiac Ischemia and Reperfusion (15 papers), Anesthesia and Neurotoxicity Research (7 papers) and Cardiac Arrest and Resuscitation (5 papers). Lydia Lacerda is often cited by papers focused on Cardiac Ischemia and Reperfusion (15 papers), Anesthesia and Neurotoxicity Research (7 papers) and Cardiac Arrest and Resuscitation (5 papers). Lydia Lacerda collaborates with scholars based in South Africa, United States and United Kingdom. Lydia Lacerda's co-authors include Lionel H. Opie, Maurizio Prato, Kostas Kostarelos, Andrea Bianco, Sandrine Lecour, Sarin Somers, Michael N. Sack, Graeme A. Deuchar, Barbara Huisamen and Kim Lamont and has published in prestigious journals such as Circulation, PLoS ONE and Circulation Research.

In The Last Decade

Lydia Lacerda

24 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Carbon nanotubes as nanomedicines: From toxicology to pharmacology☆

2006 615 citations Lydia Lacerda, Andrea Bianco et al. Advanced Drug Delivery Reviews profile →

Peers

Countries citing papers authored by Lydia Lacerda

Since Specialization

Citations

This map shows the geographic impact of Lydia Lacerda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydia Lacerda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydia Lacerda more than expected).

Fields of papers citing papers by Lydia Lacerda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydia Lacerda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydia Lacerda. The network helps show where Lydia Lacerda may publish in the future.

Co-authorship network of co-authors of Lydia Lacerda

This figure shows the co-authorship network connecting the top 25 collaborators of Lydia Lacerda. A scholar is included among the top collaborators of Lydia Lacerda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydia Lacerda. Lydia Lacerda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Role of nuclear factor kappa-B in TNF-induced cytoprotection 2023 ·Cardiovascular journal of South Africa ·Róisín Kelly‐Laubscher, Sarin Somers, Lydia Lacerda, Sandrine Lecour	3
2	Trimetazidine therapy for diabetic mouse hearts subjected to ex vivo acute heart failure 2017 ·PLoS ONE ·(unknown), Lydia Lacerda, M. Faadiel Essop	2
3	The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects 2014 ·Journal of Human Hypertension ·Dike Ojji, Lionel H. Opie, Sandrine Lecour, Lydia Lacerda, (unknown), Karen Sliwa	30
4	The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects : cardiovascular topic 2014 ·Cardiovascular journal of South Africa ·Dike Ojji, Lionel H. Opie, Sandrine Lecour, Lydia Lacerda, (unknown), Karen Sliwa	5
5	HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity 2013 ·Atherosclerosis ·Miguel A. Frias, Sarah Pedretti, Damian Hacking, Sarin Somers, Lydia Lacerda, Lionel H. Opie, Richard W. James, Sandrine Lecour	47
6	Relationship Between Left Ventricular Geometry and Soluble ST2 in a Cohort of Hypertensive Patients 2013 ·Journal of Clinical Hypertension ·Dike Ojji, Lionel H. Opie, Sandrine Lecour, Lydia Lacerda, (unknown), Karen Sliwa	23
7	Interplay Between SAFE and RISK Pathways in Sphingosine-1-Phosphate–Induced Cardioprotection 2012 ·Cardiovascular Drugs and Therapy ·Sarin Somers, Miguel A. Frias, Lydia Lacerda, Lionel H. Opie, Sandrine Lecour	71
8	Is red wine a SAFE sip away from cardioprotection? Mechanisms involved in resveratrol‐ and melatonin‐induced cardioprotection 2011 ·Journal of Pineal Research ·Kim Lamont, Sarin Somers, Lydia Lacerda, Lionel H. Opie, Sandrine Lecour	75
9	Ethanolamine is a novel STAT-3 dependent cardioprotective agent 2010 ·Basic Research in Cardiology ·Róisín Kelly‐Laubscher, Kim Lamont, Sarin Somers, Damian Hacking, Lydia Lacerda, Paul E. Thomas, Lionel H. Opie, Sandrine Lecour	49
10	TNFα protects cardiac mitochondria independently of its cell surface receptors 2010 ·Basic Research in Cardiology ·Lydia Lacerda, Joy McCarthy, (unknown), Edward G. Lynn, Michael N. Sack, Lionel H. Opie, Sandrine Lecour	38
11	Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway 2009 ·Cardiovascular Research ·Lydia Lacerda, Sarin Somers, Lionel H. Opie, Sandrine Lecour	208
12	Use of lithium carbonate in the treatment of a suspected case of oestrogen‐induced bone marrow aplasia in a bitch 2009 ·Veterinary Record ·(unknown), (unknown), Lydia Lacerda, (unknown), (unknown), Félix González	2
13	Signal transducer and activator of transcription 3 is involved in the cardioprotective signalling pathway activated by insulin therapy at reperfusion 2008 ·Basic Research in Cardiology ·(unknown), (unknown), Crina Tiron, (unknown), Lydia Lacerda, (unknown), Michael N. Sack, Anne K. Jonassen, Ole D. Μjøs, Lionel H. Opie, Sandrine Lecour	81
14	TNFα can mimic ischaemic postconditioning 2008 ·Journal of Molecular and Cellular Cardiology ·Lydia Lacerda, Lionel H. Opie, Sandrine Lecour	1
15	Ischaemic postconditioning requires TNF activation to confer protection 2007 ·Journal of Molecular and Cellular Cardiology ·Lydia Lacerda, Lionel H. Opie, Sandrine Lecour	2
16	TNFα-induced cytoprotection requires the production of free radicals within mitochondria in C2C12 myotubes 2006 ·Life Sciences ·Lydia Lacerda, Robert M. Smith, Lionel H. Opie, Sandrine Lecour	23
17	Carbon nanotubes as nanomedicines: From toxicology to pharmacology☆ breakdown → 2006 ·Advanced Drug Delivery Reviews ·Lydia Lacerda, Andrea Bianco, Maurizio Prato, Kostas Kostarelos	615
18	Diazoxide-induced respiratory inhibition – a putative mitochondrial KATP channel independent mechanism of pharmacological preconditioning 2006 ·Molecular and Cellular Biochemistry ·Jan Minners, Lydia Lacerda, Derek M. Yellon, Lionel H. Opie, Christopher J. McLeod, Michael N. Sack	41
19	Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning 2004 ·Cardiovascular Research ·Robert Smith, (unknown), Lydia Lacerda, L OPIE, (unknown), Kuo‐Liong Chien, Michael N. Sack	109
20	Ischemic and Pharmacological Preconditioning in Girardi Cells and C2C12 Myotubes Induce Mitochondrial Uncoupling 2001 ·Circulation Research ·Jan Minners, Lydia Lacerda, Joy McCarthy, (unknown), Derek M. Yellon, Michael N. Sack	69

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact